Lek receives TOP Education Investor certificate
- Lek is a recipient of the TOP EducationInvestor certificate, which is awarded to companies that invest above averagein education and employee development.
- The certificate confirms Lek's long-term planned investment in education, training and personal development ofits employees, which is crucial for the company's growth and development.
- Lek, a Sandoz company is committed to creating a supportive and high-quality work environment that enables all employees to be the best version of themselves.
As one of the most reputable employers in Slovenia, Lek is consistently recognized for its HR practices. Its latest accolade is the TOP Education Investor certificate, awarded by Planet GV and the Sofos Education Management Institute. The certificate recognizes companies that make exceptional investments into education and employee development.
The TOP Education Investor certificate is a testament to our long-standing and systematic investment into associates' education, training and personal development. We at Lek are well aware that constant learning, training and betterment of our associates is key to our company’s growth and development, and allows us to successfully tackle the challenges in the rapidly changing pharmaceutical industry. This is backed by the fact that in the year 2022 alone, Lek associates took part in 416,144 learning hours.
“By living the Sandoz values, we aim to bring out the best in our associates. We are ambitious and driven by progress and new opportunities, while at the same time devoted to creating a working environment that allows each one of us to be the best version of ourselves. It is our firm belief that regular education drives progress. Our associates are given numerous opportunities to expand on their knowledge and we are proud that most of them respond favorably,” said Fikret Bašanović, P&O People Partner in education.
Building on existing knowledge and investing in new learning opportunities remain our top priorities on the way to fulfilling our goal – becoming the world’s leading and most valued generics and biosimilars company.
About Lek
Lek, a Sandoz company, is the first and oldest pharmaceutical company in Slovenia, developing, manufacturing and marketing effective, safe and high-quality generics and biosimilars for patients around the world. Our work is guided by strong ethical standards, innovative thinking and the breakthrough achievements of our world-class professionals. With more than 3,700 associates, we have been actively shaping the Slovenian, European and global research and development landscape for decades. We are building a culture of open dialog, and we proudly and responsibly hold the title of most reputable employer in Slovenia.
About Sandoz
Sandoz (SIX: SDZ; OTCQX: SDZNY) is the global leader in generic and biosimilar medicines, with a growth strategy driven by its Purpose: pioneering access for patients. 22,000 people of more than 100 nationalities work together to bring Sandoz medicines to some 500million patients worldwide, generating substantial global healthcare savings and making an even larger total social impact. Its leading portfolio of more than 1,500 products addresses diseases from the common cold to cancer.Headquartered in Basel, Switzerland, Sandoz traces its heritage back to the year 1886. Its history of breakthroughs includes Calcium Sandoz in 1929, the world’s first oral penicillin in 1951, and the world’s first biosimilar in2006. In 2022, Sandoz achieved sales of USD 9.1 billion and core EBITDA of USD1.9 billion.
Disclaimer
This Media Release contains forward-looking statements which offer no guarantee with regard to future performance. These statements are made on the basis of management’s views and assumptions regarding future events and business performance at the time the statements are made. They are subject to risks and uncertainties including, but not confined to, future global economic conditions, exchange rates, legal provisions, market conditions, activities by competitors and other factors outside of the control of Sandoz. Should one or more of these risks or uncertainties materialize or should underlying assumptions prove incorrect, actual outcomes may vary materially from those forecasted or expected. Each forward-looking statement speaks only as of the date of the particular statement, and Sandoz undertakes no obligation to publicly update or revise any forward-looking statements, except as required by law.
